Ocrevus: Counting Down to Expected FDA Approval
Ocrevus: Counting Down to Expected FDA Approval
There is now less than a month until the U.S. Food and Drug Administration (FDA) is expected to approve Ocrevus, generic name ocrelizumab, for use as a therapy for multiple sclerosis.
Clinical trials have shown Genentech’s drug to be a promising therapy for relapsing MS and, significantly, the primary progressive form of the disease for which there is no approved treatment.
The FDA is due to…
View On WordPress










